Fibrotic response in fibroblasts from congenital disorders of glycosylation

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 8, 2011, Pages 1788-1796

  Lecca, M Rita ^a   Maag, Charlotte ^a   Berger, Eric G ^a   Hennet, Thierry ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

CDG; Collagen; Fibroblast; IGFBP5; Transcriptome

Indexed keywords

BIGLYCAN; CARTILAGE MATRIX PROTEIN; COLLAGEN TYPE 1; GLYCOPROTEIN; RECOMBINANT PROTEIN; SCLEROPROTEIN; SOMATOMEDIN BINDING PROTEIN 5; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL CULTURE; CLUSTER ANALYSIS; CONGENITAL DISORDER OF GLYCOSYLATION; DNA MICROARRAY; DRUG EFFECT; FIBROBLAST; FIBROSIS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

BIGLYCAN; BLOTTING, WESTERN; CELLS, CULTURED; CLUSTER ANALYSIS; COLLAGEN TYPE I; CONGENITAL DISORDERS OF GLYCOSYLATION; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; FIBROSIS; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 79960338992     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01187.x     Document Type: Article

References (58)

1. Burda P, Aebi M. The dolichol pathway of N-linked glycosylation. Biochim Biophys Acta. 1999; 1426: 239-57.
2. Spiro RG. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology. 2002; 12: 43R-56R.
3. Kretz KA, Carson GS, Morimoto S, et al. Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. Proc Natl Acad Sci USA. 1990; 87: 2541-4.
4. Bayston TA, Tripodi A, Mannucci PM, et al. Familial overexpression of beta antithrombin caused by an Asn135Thr substitution. Blood. 1999; 93: 4242-7.
5. Bertina RM, Ploos van Amstel HK, van Wijngaarden A, et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood. 1990; 76: 538-48.
6. Lovegrove JU, Jeremiah S, Gillett GT, et al. A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI Zbristol) associated with novel electrophoretic properties. Ann Hum Genet. 1997; 61: 385-91.
7. Vogt G, Chapgier A, Yang K, et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet. 2005; 37: 692-700.
8. Aebi M, Hennet T. Congenital disorders of glycosylation: genetic model systems lead the way. Trends Cell Biol. 2001; 11: 136-41.
9. Jaeken J, Matthijs G. Congenital disorders of glycosylation: a rapidly expanding disease family. Annu Rev Genomics Hum Genet. 2007; 8: 261-78.
10. Freeze HH. Genetic defects in the human glycome. Nat Rev Genet. 2006; 7: 537-51.
11. Eklund EA, Freeze HH. The congenital disorders of glycosylation: a multifaceted group of syndromes. NeuroRx. 2006; 3: 254-63.
12. Kornak U, Reynders E, Dimopoulou A, et al. Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. Nat Genet. 2008; 40: 32-4.
13. Schenk B, Imbach T, Frank CG, et al. MPDU1mutations underlie a novel human congenital disorder of glycosylation (CDG), designated type If. J Clin Invest. 2001; 108: 1687-95.
14. Westphal V, Murch S, Kim S, et al. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am J Pathol. 2000; 157: 1917-25.
15. Lau KS, Partridge EA, Grigorian A, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007; 129: 123-34.
16. Ohtsubo K, Takamatsu S, Minowa MT, et al. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell. 2005; 123: 1307-21.
17. Partridge EA, Le Roy C, Di Guglielmo GM, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 2004; 306: 120-4.
18. Wang X, Inoue S, Gu J, et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA. 2005; 102: 15791-6.
19. Mills P, Mills K, Clayton P, et al. Congenital disorders of glycosylation type I leads to altered processing of N-linked glycans, as well as underglycosylation. Biochem J. 2001; 359: 249-54.
20. Callewaert N, Schollen E, Vanhecke A, et al. Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I. Glycobiology. 2003; 13: 367-75.
21. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004; 18: 816-27.
22. Brigstock DR. The CCN family: a new stimulus package. J Endocrinol. 2003; 178: 169-75.
23. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001; 19: 816-27.
24. Imbach T, Schenk B, Schollen E, et al. Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie. J Clin Invest. 2000; 105: 233-9.
25. Kim S, Westphal V, Srikrishna G, et al. Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie). J Clin Invest. 2000; 105: 191-8.
26. Grubenmann CE, Frank CG, Kjaergaard S, et al. ALG12 mannosyltransferase defect in congenital disorder of glycosylation type lg. Hum Mol Genet. 2002; 11: 2331-9.
27. Thiel C, Schwarz M, Hasilik M, et al. Deficiency of dolichyl-P-Man: Man7GlcNAc2-PP-dolichyl mannosyltransferase causes congenital disorder of glycosylation type Ig. Biochem J. 2002; 367: 195-201.
28. Chantret I, Dupre T, Delenda C, et al. Congenital disorders of glycosylation type Ig is defined by a deficiency in dolichyl-P-mannose: Man7GlcNAc2-PP-dolichyl mannosyltransferase. J Biol Chem. 2002; 277: 25815-22.
29. Imbach T, Burda P, Kuhnert P, et al. A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic. Proc Natl Acad Sci USA. 1999; 96: 6982-7.
30. Lecca MR, Wagner U, Patrignani A, et al. Genome-wide analysis of the unfolded protein response in fibroblasts from congenital disorders of glycosylation type-I patients. FASEB J. 2005; 19: 240-2.
31. Hubbell E, Liu WM, Mei R. Robust estimators for expression analysis. Bioinformatics. 2002; 18: 1585-92.
32. Liu WM, Mei R, Di X, et al. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics. 2002; 18: 1593-9.
33. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001; 125: 279-84.
34. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979; 76: 4350-4.
35. Thompson JA. Molecular cloning and expression of carcinoembryonic antigen gene family members. Tumour Biol. 1995; 16: 10-6.
36. Larsson M, Stahl S, Uhlen M, et al. Expression profile viewer (ExProView): a software tool for transcriptome analysis. Genomics. 2000; 63: 341-53.
37. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, et al. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem. 2002; 277: 29197-209.
38. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007; 170: 1807-16.
39. Pilewski JM, Liu L, Henry AC, et al. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol. 2005; 166: 399-407.
40. Kristiansson B, Borulf S, Conradi N, et al. Intestinal, pancreatic and hepatic involvement in carbohydrate-deficient glycoprotein syndrome type I. J Pediatr Gastroenterol Nutr. 1998; 27: 23-9.
41. Iancu TC, Mahajnah M, Manov I, et al. The liver in congenital disorders of glycosylation: ultrastructural features. Ultrastruct Pathol. 2007; 31: 189-97.
42. de Lonlay P, Seta N. The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochim Biophys Acta. 2009; 1792: 841-3.
43. Grunewald S. The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta. 2009; 1792: 827-34.
44. Farina G, Lemaire R, Korn JH, et al. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol. 2006; 25: 213-22.
45. Canfield AE, Farrington C, Dziobon MD, et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol. 2002; 196: 228-34.
46. Liao Q, Kleeff J, Xiao Y, et al. COMP is selectively up-regulated in degenerating acinar cells in chronic pancreatitis and in chronic-pancreatitis-like lesions in pancreatic cancer. Scand J Gastroenterol. 2003; 38: 207-15.
47. Hecht JT, Nelson LD, Crowder E, et al. Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. Nat Genet. 1995; 10: 325-9.
48. Feghali CA, Wright TM. Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum. 1999; 42: 1451-7.
49. Yasuoka H, Jukic DM, Zhou Z, et al. Insulin-like growth factor binding protein 5 induces skin fibrosis: a novel murine model for dermal fibrosis. Arthritis Rheum. 2006; 54: 3001-10.
50. Sureshbabu A, Okajima H, Yamanaka D, et al. IGFBP-5 induces epithelial and fibroblast responses consistent with the fibrotic response. Biochem Soc Trans. 2009; 37: 882-5.
51. Beattie J, Allan GJ, Lochrie JD, et al. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 2006; 395: 1-19.
52. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23: 824-54.
53. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol. 2001; 54: 133-7.
54. Jones JI, Gockerman A, Busby WH Jr., et al. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol. 1993; 121: 679-87.
55. Arai T, Parker A, Busby W Jr., et al. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem. 1994; 269: 20388-93.
56. Allan GJ, Beattie J, Flint DJ. Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGF-binding protein-5. J Endocrinol. 2008; 199: 155-64.
57. Fonseca C, Lindahl GE, Ponticos M, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med. 2007; 357: 1210-20.
58. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010; 21: 212-22.